8-K: Owens & Minor Announces Sale Process for Products & Healthcare Services Segment Amidst Debt Reduction and Positive 2025 Outlook

Owens & Minor is exploring the sale of its Products & Healthcare Services segment while reporting a significant debt reduction and projecting double-digit growth in adjusted EBITDA and EPS for 2025.

Summary

• Owens & Minor reported its financial results for the fourth quarter and full year 2024.
• The company is actively engaged in discussions regarding the potential sale of its Products & Healthcare Services (P&HS) segment.
• In 2024, Owens & Minor reduced its total debt by $244 million, bringing the two-year total debt reduction to $647 million.
• The Board of Directors has authorized a share repurchase program of up to $100 million over the next 24 months.
• The company's 2025 financial outlook includes revenue in the range of $10.85 billion to $11.15 billion.
• Adjusted EBITDA for 2025 is projected to be between $560 million and $590 million.
• Adjusted EPS for 2025 is expected to be in the range of $1.60 to $1.85.
• The 2025 outlook excludes any impact from the Rotech acquisition, the potential sale of the P&HS segment, or share repurchase activity.
• Key assumptions supporting the 2025 financial guidance include a gross margin of 20.75% to 21.25%, interest expense of $138 million to $142 million, and an adjusted effective tax rate of 29.0% to 30.0%.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While the company reported a net loss for 2024, the focus on debt reduction, potential asset sale, and positive 2025 outlook suggest a strategic shift towards improved financial performance. The share repurchase program also signals confidence in the company's future prospects.

Positives

• The company has made progress against its strategy as outlined at its Investor Day in December 2023.
• Total debt reduction of $244 million in 2024, capping a two-year total debt reduction of $647 million.
• The company is actively engaged in robust discussions regarding the potential sale of its Products & Healthcare Services segment.
• The company is confident in its ability to achieve double-digit adjusted EBITDA growth while improving cash flow.
• The Board of Directors authorized a share repurchase program of up to $100 million.
• The company's 2025 financial outlook includes revenue in the range of $10.85 billion to $11.15 billion.
• Adjusted EBITDA for 2025 is projected to be between $560 million and $590 million.
• Adjusted EPS for 2025 is expected to be in the range of $1.60 to $1.85.

Negatives

• The company reported a GAAP operating loss of $208 million for 2024.
• The company reported a GAAP net loss of $363 million for 2024.
• The company reported a goodwill impairment charge of $305 million, net of tax.
• Net loss per common share was $(4.73).

Risks

• The company's ability to successfully complete the sale of the P&HS business in any specific transaction on favorable terms or at all is uncertain.
• The company's ability to raise additional financing for its acquisition of Rotech on favorable terms or at all is uncertain.
• The risk that the proposed acquisition of Rotech will not be consummated in a timely manner or at all is a concern.
• The company's expectations regarding the performance of its business, including its ability to address macro and market conditions, may not be realized.
• Forward-looking statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those projected.

Future Outlook

The company expects revenue between $10.85 billion and $11.15 billion, adjusted EBITDA between $560 million and $590 million, and adjusted EPS between $1.60 and $1.85 for 2025. This outlook excludes the impact of the Rotech acquisition, the potential sale of the P&HS segment, and any share repurchase activity.

Management Comments

• Edward A. Pesicka, President & Chief Executive Officer of Owens & Minor, stated that the company is pleased with the progress made against the strategy outlined at the Investor Day in December 2023.
• Pesicka added that the company is committed to directing capital toward the higher growth and higher margin Patient Direct segment.
• Pesicka concluded that the company remains focused on delivering a strong 2025 and is confident in its ability to achieve double-digit adjusted EBITDA growth while improving cash flow.

Industry Context

The potential sale of the Products & Healthcare Services segment reflects a strategic shift towards the higher-growth Patient Direct segment, aligning with broader industry trends favoring home-based care and chronic condition management. This move could position Owens & Minor more competitively against companies focused on direct-to-patient healthcare solutions.

Comparison to Industry Standards

• The company's debt reduction efforts are commendable, as many healthcare distributors carry significant debt loads.
• Companies like Cardinal Health and McKesson also operate in the healthcare distribution space, but Owens & Minor's strategic focus on Patient Direct differentiates it.
• The projected adjusted EBITDA growth for 2025 is a positive sign, as some competitors are facing margin pressures due to rising costs and supply chain disruptions.

Stakeholder Impact

• Shareholders may be impacted by the potential sale of the P&HS segment and the share repurchase program.
• Employees in the P&HS segment may be affected by the potential sale.
• Customers may experience changes in product offerings and services as a result of the strategic shift.
• Suppliers may be impacted by changes in the company's product portfolio and supply chain.

Next Steps

• The company will continue discussions regarding the potential sale of its Products & Healthcare Services segment.
• The company will focus on delivering a strong 2025 and achieving its financial outlook.
• The company will execute its share repurchase program over the next 24 months.
• The company will file its Annual Report on Form 10-K for the year ended December 31, 2024, with the SEC on or around February 28, 2025.

Key Dates